World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
33698
World Ranking
13022
National Ranking
182

Overview

Rolf A. Stahel is affiliated with the University of Zurich in Switzerland and has a research profile primarily focused on medicine, with a significant emphasis on pulmonary and respiratory medicine and oncology. Their publication record spans several subfields, including cancer research, radiology, nuclear medicine, and even economics and econometrics.

The scientist's work is centered around key topics such as lung cancer treatments and mutations, occupational and environmental lung diseases, lung cancer diagnosis and treatment, cancer immunotherapy and biomarkers, lung cancer research studies, pleural and pulmonary diseases, and cancer genomics and diagnostics.

Recent publications by Rolf A. Stahel reflect ongoing contributions to oncology and respiratory medicine through clinical trial reports and guideline papers. Notable papers include:

  • Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial, 2022, The Lancet Oncology
  • EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours, 2021, Annals of Oncology
  • A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial, 2020, Annals of Oncology
  • ESMO Guidance for Reporting Oncology real-World evidence (GROW), 2023, Annals of Oncology
  • Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14), 2020, Journal of Thoracic Oncology

They frequently collaborate with other researchers, notably Solange Peters, Urania Dafni, Heidi Roschitzki-Voser, Barbara Ruepp, and Roswitha Kammler. These collaborations have contributed to a substantial body of work within the domains of lung cancer and oncology.

Rolf A. Stahel's research is frequently published in specialized venues, indicating a focused engagement with the academic community in thoracic oncology and respiratory medicine. The most common publication venues include:

  • Lung Cancer
  • Annals of Oncology
  • Journal of Thoracic Oncology
  • Journal of Clinical Oncology
  • Cancer Treatment Reviews

The scientist's body of work encompasses a broad spectrum of lung and cancer-related medical research, underscoring an emphasis on clinical trials, treatment protocols, and diagnostic guidelines within respiratory medicine and oncology.

Best Publications

  • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

    Michael Pfreundschuh;Lorenz Trümper;Anders Österborg;Ruth Pettengell

  • DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

    Ken A. Olaussen;Ariane Dunant;Pierre Fouret;Elisabeth Brambilla

  • CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

    Michael Pfreundschuh;Evelyn Kuhnt;Lorenz Trümper;Anders Österborg

  • Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

    A Scherpereel;P Astoul;P Baas;T Berghmans

  • Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial

    Daniel C. Betticher;Shu Fang Hsu Schmitz;Martin Tötsch;Eva Hansen

  • 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    J. Vansteenkiste;L. Crinò;C. Dooms;J. Y. Douillard

  • Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.

    Viviana Galimberti;Bernard F Cole;Giuseppe Viale;Giuseppe Viale;Paolo Veronesi;Paolo Veronesi

  • CD24, a Mucin-Type Glycoprotein, Is a Ligand for P-Selectin on Human Tumor Cells

    Silke Aigner;Zev M. Sthoeger;Mina Fogel;Erich Weber

  • 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

    W.E.E. Eberhardt;D. De Ruysscher;W. Weder;C. Le Péchoux

  • Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    P. Baas;D. Fennell;K. M. Kerr;P. E. Van Schil

  • Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.

    T Le Chevalier;G Scagliotti;R Natale;S Danson

  • Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

    Sherene Loi;Anita Giobbie-Hurder;Andrea Gombos;Thomas Bachelot

  • Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma

    W Weder;R A Stahel;J Bernhard;S Bodis

  • Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

    Miklos Pless;Roger Stupp;Roger Stupp;Hans Beat Ris;Rolf A. Stahel

  • Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop

    Robert Pirker;Felix J F Herth;Keith M. Kerr;Martin Filipits

  • CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

    J Lundin;Anders Osterborg;G Brittinger;Derek Crowther

  • Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

    Keith M. Kerr;Lukas Bubendorf;Martin J. Edelman;Antonio Marchetti

  • High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment.

    J Willuda;A Honegger;R Waibel;P A Schubiger

  • Circulating Deoxyribonucleic Acid As Prognostic Marker in Non–Small-Cell Lung Cancer Patients Undergoing Chemotherapy

    Oliver Gautschi;Colette Bigosch;Barbara Huegli;Monika Jermann

  • Staging and prognostic factors in small cell lung cancer: a consensus report

    Rolf Arno R. Stahel;Robert Ginsberg;Klaus Havemann;Fred R Hirsch

Frequent Co-Authors

Walter Weder
Walter Weder University of Zurich
Solange Peters
Solange Peters University Hospital of Lausanne
Lukas Bubendorf
Lukas Bubendorf University Hospital of Basel
Uwe Zangemeister-Wittke
Uwe Zangemeister-Wittke University of Bern
Keith M. Kerr
Keith M. Kerr Aberdeen Royal Infirmary
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Roger Stupp
Roger Stupp Northwestern University
Rafael Rosell
Rafael Rosell Autonomous University of Barcelona
Fiona H Blackhall
Fiona H Blackhall University of Manchester
Paul Baas
Paul Baas Antoni van Leeuwenhoek Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing medicine in the USA opens the door to diverse online degrees and accelerated career pathways, especially in nursing and healthcare leadership. If you’re ready to advance your clinical expertise, a 1 year dnp program online offers a fast-track approach to earning your Doctor of Nursing Practice. For those seeking less intensive options, the easiest online dnp programs may provide a balanced track while still delivering high-quality education.

Students interested in entering the workforce sooner might consider fast track lpn programs, which prepare you for practical nursing quickly and efficiently. Specializations are also in demand; for example, aspiring psychiatric nurse practitioners can explore fast track mental health nursing programs to make a difference in mental health care settings.

Whether you’re aiming for hands-on patient care or leadership roles, these online pathways offer the flexibility and speed to help you achieve your goals in the dynamic field of medicine.

Best Scientists Citing Rolf A. Stahel

Trending Scientists

Recently Published Articles